Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.ENVB · Entity 8193 | Director | June 01, 2026 | June 03, 2026 |
| Keenova Therapeutics plcMNK · Entity 28960 | EVP & CFO, Interim | January 09, 2019 | January 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,418 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 18,518 · Balance 26,418 F1: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Keenova Therapeutics plc
Report date January 09, 2019 · Filed January 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,985 |
Reported balance
After 2019-01-09 transaction · row 1
1 source rowRow 1 · 2019-01-09 · Tax withholding · Disposed 81 · Balance 14,985 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 18,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001761753-26-000003 · ownership.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,418 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:41 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 7,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337182 · ownership.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 23:21 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 47,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025061 · form4-10112024_111015.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,053 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 00:35 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 15,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-004178 · ownership.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,957 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:39 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 81 | $19.27 | $1,560.87 |
DisclosureSEC source: 0000950138-19-000037 · edgar.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · EVP & CFO, Interim 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,985 Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 23:22 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 98 | $17.21 | $1,686.58 |
DisclosureSEC source: 0000950138-19-000031 · edgar.xml · nonDerivative · entry 2 Kegler George A. · CIK 0001761753 · EVP & CFO, Interim 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,066 Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 23:22 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 151 | $16.14 | $2,437.14 |
DisclosureSEC source: 0000950138-19-000031 · edgar.xml · nonDerivative · entry 1 Kegler George A. · CIK 0001761753 · EVP & CFO, Interim 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,164 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.